Skip to main content
Erschienen in: International Journal of Diabetes in Developing Countries 3/2015

01.11.2015 | Original Article

Oxidant and antioxidant parameters in prediabetes and diabetes

verfasst von: Said Sami Erdem, Aysun Toker, Mehmet Kayrak, Hümeyra Çiçekler, Gülsüm Gönülalan, Turyan Abdulhalikov, Fatma Hümeyra Yerlikaya, Ahmet Kaya

Erschienen in: International Journal of Diabetes in Developing Countries | Sonderheft 3/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of our study was to evaluate serum paraoxonase (PON1), total antioxidant status (TAS), total oxidant status (TOS), and ischemia-modified albumin (IMA) levels in patients with prediabetes, diabetes, and in healthy control subjects. The subjects were aged between 20 and 60 years. Forty diabetic subjects (mean age 46.6 ± 9.7 years), 39 prediabetic subjects (mean age 44.0 ± 9.3 years) and 24 healthy control subjects (mean age 43.7 ± 9.7 years). Lipid profile, PON1, TAS, TOS and IMA levels were measured. The serum TOS and IMA levels in diabetes were significantly higher than those of the control subjects (P = 0.024 and P = 0.012, respectively), while the serum PON1 levels of the diabetes patients were significantly lower than those of the control subjects (P = 0.039). The serum TOS levels of the diabetes patients were significantly higher than those of the subjects with prediabetes (P = 0.013). There were no significant differences between the serum IMA and PON1 levels of the prediabetes and diabetes groups (P = 0.075 and P = 0.110, respectively). The serum TAS levels of the three groups were similar. The present study demonstrated that in diabetes there is greater oxidative stress. Patients with type 2 diabetes had higher TOS and IMA levels, but lower PON1 values, than controls. There were no differences in oxidative stress markers between prediabetic patients and healthy subjects.
Literatur
1.
Zurück zum Zitat American Diabetes Association. Diagnosis classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1:62–7.CrossRef American Diabetes Association. Diagnosis classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1:62–7.CrossRef
2.
Zurück zum Zitat Groop LC. The molecular genetics of non-insulin-dependent diabetes mellitus. J Intern Med. 1997;241:95–101.PubMedCrossRef Groop LC. The molecular genetics of non-insulin-dependent diabetes mellitus. J Intern Med. 1997;241:95–101.PubMedCrossRef
3.
Zurück zum Zitat Powers AC. Diabetes mellitus. In: Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 15th ed. New York: McGraw Hill; 2001. p. 2109–37. Powers AC. Diabetes mellitus. In: Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 15th ed. New York: McGraw Hill; 2001. p. 2109–37.
4.
Zurück zum Zitat Lin J, Zhang M, Song F, Qin J, et al. Association between C-reactive protein and prediabetic status in a Chinese Han clinical population. Diabetes Metab Res Rev. 2008;25:219–23.CrossRef Lin J, Zhang M, Song F, Qin J, et al. Association between C-reactive protein and prediabetic status in a Chinese Han clinical population. Diabetes Metab Res Rev. 2008;25:219–23.CrossRef
5.
Zurück zum Zitat Okopien B, Stachura-Kulach A, Kulach AJ, et al. The risk of atherosclerosis in patients with impaired glucose tolerance. Res Commun Mol Pathol Pharmacol. 2003;113–114:87–95.PubMed Okopien B, Stachura-Kulach A, Kulach AJ, et al. The risk of atherosclerosis in patients with impaired glucose tolerance. Res Commun Mol Pathol Pharmacol. 2003;113–114:87–95.PubMed
6.
Zurück zum Zitat Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, et al. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009;52:415–24.PubMedCrossRef Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, et al. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009;52:415–24.PubMedCrossRef
7.
Zurück zum Zitat The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–21.CrossRef The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–21.CrossRef
8.
Zurück zum Zitat Hyvarinen M, Qiao Q, Tuomilehto J, Laatikainen T, et al. Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria. Diabetes Care. 2009;32:348–54.PubMedPubMedCentralCrossRef Hyvarinen M, Qiao Q, Tuomilehto J, Laatikainen T, et al. Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria. Diabetes Care. 2009;32:348–54.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Primo-Parma SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33:498–509.CrossRef Primo-Parma SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33:498–509.CrossRef
10.
Zurück zum Zitat Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 1996;7:69–76.PubMedCrossRef Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 1996;7:69–76.PubMedCrossRef
11.
Zurück zum Zitat Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler, Thromb, Vasc Biol. 2001;21:473–80.CrossRef Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler, Thromb, Vasc Biol. 2001;21:473–80.CrossRef
12.
Zurück zum Zitat Mackness MI, Harty D, Bhatnagar D, Winocour PH, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193–9.PubMedCrossRef Mackness MI, Harty D, Bhatnagar D, Winocour PH, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193–9.PubMedCrossRef
13.
Zurück zum Zitat Tomas M, Latorre G, Senti M, Marrugat J. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol. 2004;57:557–69.PubMedCrossRef Tomas M, Latorre G, Senti M, Marrugat J. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol. 2004;57:557–69.PubMedCrossRef
14.
Zurück zum Zitat Mackness B, Durrington PN, Boulton AJ, Hine D, et al. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest. 2002;32:259–64.PubMedCrossRef Mackness B, Durrington PN, Boulton AJ, Hine D, et al. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest. 2002;32:259–64.PubMedCrossRef
15.
Zurück zum Zitat Abbott CA, Mackness MI, Kumar S, Boulton AJ, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscl Thromb Vasc Biol. 1995;15:1812–8.PubMedCrossRef Abbott CA, Mackness MI, Kumar S, Boulton AJ, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscl Thromb Vasc Biol. 1995;15:1812–8.PubMedCrossRef
16.
Zurück zum Zitat Inoue M, Suehiro T, Nakamura T, Ikeda Y, et al. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism. 2000;49:1400–5.PubMedCrossRef Inoue M, Suehiro T, Nakamura T, Ikeda Y, et al. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism. 2000;49:1400–5.PubMedCrossRef
17.
Zurück zum Zitat Telci A, Cakatay U, Kayali R, Erdoğan C, et al. Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab Res. 2000;32:40–3.PubMedCrossRef Telci A, Cakatay U, Kayali R, Erdoğan C, et al. Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab Res. 2000;32:40–3.PubMedCrossRef
18.
Zurück zum Zitat Mackness B, Durrington PN, Abuashia B, Boulton AJ, et al. Low paraoxonase activity in type 2 diabetes mellitus complicated by retinopathy. Clin Sci. 2000;98:355–63.PubMedCrossRef Mackness B, Durrington PN, Abuashia B, Boulton AJ, et al. Low paraoxonase activity in type 2 diabetes mellitus complicated by retinopathy. Clin Sci. 2000;98:355–63.PubMedCrossRef
19.
Zurück zum Zitat Manfredini V, Biancini GB, Vanzin CS, Dal Vesco AM, et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients. Cell Biochem Funct. 2010;28:360–6.PubMedCrossRef Manfredini V, Biancini GB, Vanzin CS, Dal Vesco AM, et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients. Cell Biochem Funct. 2010;28:360–6.PubMedCrossRef
20.
Zurück zum Zitat Camuzcuoglu H, Toy H, Cakir H, Celik H, et al. Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus. J Womens Health (Lanchmt). 2009;18:1435–9.CrossRef Camuzcuoglu H, Toy H, Cakir H, Celik H, et al. Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus. J Womens Health (Lanchmt). 2009;18:1435–9.CrossRef
21.
Zurück zum Zitat Patel BN, Mackness MI, Harty DW, Arrol S, et al. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta. 1990;1035:113–6.PubMedCrossRef Patel BN, Mackness MI, Harty DW, Arrol S, et al. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta. 1990;1035:113–6.PubMedCrossRef
22.
Zurück zum Zitat Chan B, Dodsworth N, Woodrow J, Tucker A, et al. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem. 1995;227:524–8.PubMedCrossRef Chan B, Dodsworth N, Woodrow J, Tucker A, et al. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem. 1995;227:524–8.PubMedCrossRef
23.
Zurück zum Zitat Roy D, Quiles J, Gaze DC, Collinson P, et al. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006;92:113–4.PubMedPubMedCentralCrossRef Roy D, Quiles J, Gaze DC, Collinson P, et al. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006;92:113–4.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker formyocardial ischemia—a preliminary report. J EmergMed. 2000;19:311–5.CrossRef Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker formyocardial ischemia—a preliminary report. J EmergMed. 2000;19:311–5.CrossRef
25.
Zurück zum Zitat Mayer B, Zitta S, Greilberger J, Holzer H, et al. Effect of hemodialysis on the antioxidative properties of serum. Biochim Biophys Acta. 2003;1638:267–72.PubMedCrossRef Mayer B, Zitta S, Greilberger J, Holzer H, et al. Effect of hemodialysis on the antioxidative properties of serum. Biochim Biophys Acta. 2003;1638:267–72.PubMedCrossRef
26.
Zurück zum Zitat Aslan M, Sabuncu T, Kocyiğit A, Celik H, et al. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2007;17:734–40.PubMedCrossRef Aslan M, Sabuncu T, Kocyiğit A, Celik H, et al. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2007;17:734–40.PubMedCrossRef
27.
Zurück zum Zitat Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112–9.PubMedCrossRef Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112–9.PubMedCrossRef
28.
Zurück zum Zitat Genuth S, Alberti KG, Bennett P, Buse J, et al. The expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.PubMedCrossRef Genuth S, Alberti KG, Bennett P, Buse J, et al. The expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.PubMedCrossRef
29.
Zurück zum Zitat Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;3:277–85.CrossRef Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;3:277–85.CrossRef
30.
Zurück zum Zitat Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–11.PubMedCrossRef Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–11.PubMedCrossRef
31.
Zurück zum Zitat Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126–38.PubMedPubMedCentral Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126–38.PubMedPubMedCentral
32.
Zurück zum Zitat Kopprasch S, Pietzch J, Kuhlisch E, Fuecker K, et al. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes. 2002;51:3102–6.PubMedCrossRef Kopprasch S, Pietzch J, Kuhlisch E, Fuecker K, et al. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes. 2002;51:3102–6.PubMedCrossRef
33.
Zurück zum Zitat Aviram M, Rosenblat M, Billecke S, Erogul J, et al. Human serum paraoxonase is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892–904.PubMedCrossRef Aviram M, Rosenblat M, Billecke S, Erogul J, et al. Human serum paraoxonase is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892–904.PubMedCrossRef
34.
Zurück zum Zitat Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J. 1995;42:461–5.PubMedCrossRef Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J. 1995;42:461–5.PubMedCrossRef
35.
Zurück zum Zitat Mackness B, Mackness MI, Arrol S, Turkie W, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998;139:341–9.PubMedCrossRef Mackness B, Mackness MI, Arrol S, Turkie W, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998;139:341–9.PubMedCrossRef
36.
Zurück zum Zitat Kurban S, Mehmetoglu I, Yerlikaya FH, Gönen S, et al. Effect of chronic regular exercise on serum ischemia-modified albumin levels and oxidative stress in type 2 diabetes mellitus. Endocr Res. 2011;36:116–23.PubMedCrossRef Kurban S, Mehmetoglu I, Yerlikaya FH, Gönen S, et al. Effect of chronic regular exercise on serum ischemia-modified albumin levels and oxidative stress in type 2 diabetes mellitus. Endocr Res. 2011;36:116–23.PubMedCrossRef
37.
Zurück zum Zitat Bolajoko EB, Mossanda KS, Adeniyi F, Akinosun O, et al. Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer. S Afr Med J. 2008;98:614–7.PubMed Bolajoko EB, Mossanda KS, Adeniyi F, Akinosun O, et al. Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer. S Afr Med J. 2008;98:614–7.PubMed
38.
Zurück zum Zitat Komosinska-Vassev K, Olczyk K, Olczyk P, et al. Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract. 2005;68:207–16.PubMedCrossRef Komosinska-Vassev K, Olczyk K, Olczyk P, et al. Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract. 2005;68:207–16.PubMedCrossRef
39.
Zurück zum Zitat Dave GS, Kalia K. Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy. Cell Mol Biol. 2007;53:68–78.PubMed Dave GS, Kalia K. Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy. Cell Mol Biol. 2007;53:68–78.PubMed
40.
Zurück zum Zitat Dogun ES, Ajala MO. Ascorbic acid and alpha tocopherol antioxidant status of type 2 diabetes mellitus patients seen in Lagos. Niger Postgrad Med J. 2005;12:155–7.PubMed Dogun ES, Ajala MO. Ascorbic acid and alpha tocopherol antioxidant status of type 2 diabetes mellitus patients seen in Lagos. Niger Postgrad Med J. 2005;12:155–7.PubMed
41.
Zurück zum Zitat Kaefer M, Piva SJ, De Carvalho JA, Da Silva DB, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem. 2010;43:450–4.PubMedCrossRef Kaefer M, Piva SJ, De Carvalho JA, Da Silva DB, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem. 2010;43:450–4.PubMedCrossRef
42.
Zurück zum Zitat Dahiya K, Aggarwal K, Seth S, Singh V, et al. Type 2 diabetes mellitus without vascular complications and ischemia modified albumin. Clin Lab. 2010;56:187–90.PubMed Dahiya K, Aggarwal K, Seth S, Singh V, et al. Type 2 diabetes mellitus without vascular complications and ischemia modified albumin. Clin Lab. 2010;56:187–90.PubMed
43.
Zurück zum Zitat Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus-Preliminary report. Dis Markers. 2008;24:311–7.PubMedPubMedCentralCrossRef Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus-Preliminary report. Dis Markers. 2008;24:311–7.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Hirsh IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complicat. 2005;19:178–81.CrossRef Hirsh IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complicat. 2005;19:178–81.CrossRef
45.
Zurück zum Zitat Hirsh IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl 5A):21S–6S.CrossRef Hirsh IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl 5A):21S–6S.CrossRef
46.
Zurück zum Zitat Bonds DE, Miller ME, Bergenstal RM, Buse JB, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.PubMedPubMedCentralCrossRef Bonds DE, Miller ME, Bergenstal RM, Buse JB, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Zoungas S, Patel A, Chalmers J, de Galan BE, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–8.PubMedCrossRef Zoungas S, Patel A, Chalmers J, de Galan BE, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–8.PubMedCrossRef
48.
Zurück zum Zitat Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334:777–83.PubMedCrossRef Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334:777–83.PubMedCrossRef
49.
Zurück zum Zitat Barclay C, Procter KL, Glendenning R, Marsh P, et al. Can type 2 diabetes be prevented in UK general practice? A lifestyle-change feasibility study (ISAIAH). Br J Gen Pract. 2008;58:541–7.PubMedPubMedCentralCrossRef Barclay C, Procter KL, Glendenning R, Marsh P, et al. Can type 2 diabetes be prevented in UK general practice? A lifestyle-change feasibility study (ISAIAH). Br J Gen Pract. 2008;58:541–7.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Norris SL, Zhang X, Avenell A, Gregg E, et al. Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review. Am J Prev Med. 2005;28:126–39.PubMedCrossRef Norris SL, Zhang X, Avenell A, Gregg E, et al. Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review. Am J Prev Med. 2005;28:126–39.PubMedCrossRef
Metadaten
Titel
Oxidant and antioxidant parameters in prediabetes and diabetes
verfasst von
Said Sami Erdem
Aysun Toker
Mehmet Kayrak
Hümeyra Çiçekler
Gülsüm Gönülalan
Turyan Abdulhalikov
Fatma Hümeyra Yerlikaya
Ahmet Kaya
Publikationsdatum
01.11.2015
Verlag
Springer India
Erschienen in
International Journal of Diabetes in Developing Countries / Ausgabe Sonderheft 3/2015
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-013-0185-4

Weitere Artikel der Sonderheft 3/2015

International Journal of Diabetes in Developing Countries 3/2015 Zur Ausgabe